Phase 2 Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 50 years or older at the time of signing the consent form
- People who have a blood marker of inflammation (called hs-CRP) measured at 2 mg/L or above at the start of the study
- People who have been diagnosed with a long-term heart condition called HFpEF (heart failure with preserved ejection fraction) within the past 6 months, confirmed by one of the following: certain heart ultrasound (echocardiogram) measurements showing changes to heart structure or function within the past 12 months; OR pressure measurements inside the heart meeting specific levels; OR a hospital stay or urgent unplanned visit in the past 9 months due to worsening heart failure requiring treatment through a drip, along with a specific heart hormone (NT-proBNP) blood test result above a set level
- People who are living in the community (not hospitalised) and are able to do a supervised exercise breathing test (called cardiopulmonary exercise testing)
- People whose heart failure medications have been at a stable, unchanged dose for at least the past month
- People whose level of physical activity has been stable
- People who take weight loss medications and have been on a stable dose of those medications
- People who have provided their informed consent before any study-related activities begin
Who may not be able to join:
- People who do not meet the inclusion criteria listed above
- People who are pregnant, breastfeeding, or considering becoming pregnant during the study period
- People with significantly reduced kidney function (eGFR below 30 mL/min)
- People with severe heart valve disease that is likely to need a procedure or surgery
- People whose life expectancy is less than one year
- People who are unable to complete the cardiopulmonary exercise test
- People with elevated liver enzyme levels (ALT or AST more than 2.5 times the upper limit of normal) at the time of screening
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ambarish Pandey, MD, University of Texas Southwestern Medical Center
Phone: 2146459762
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Peak VO2 indexed to body weight
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.